pharmaphorum

OCTOBER 30, 2019

While combo approaches aren’t new, there are significant cost implications of combining high priced innovator drugs (versus older, generic chemotherapies). Overview Oncology treatment increasingly involves combinations of novel oral and biologic drugs. Payers are in a difficult spot regarding the cost and management of these regimens.

Chemotherapy 40

Chemotherapy 40

Hospital Pharmacy Europe

NOVEMBER 4, 2024

Durvalumab is ‘promising step forward’ The latest approval from the MHRA is based on positive data from the AEGEAN Phase III trial in rNSCLC , which showed that durvalumab-based treatment before and after surgery reduced the risk of recurrence, progression events or death by 32% versus neoadjuvant chemotherapy alone.

Chemotherapy 52

Chemotherapy Patient Care Clinic Management Hospitals 52

ISPE

NOVEMBER 1, 2022

The trial at that time involved high doses of vitamin D with chemotherapy, and began with chemo, then surgery, recuperation, more chemo, and finally radiation. The traditional path at the time of his diagnosis was surgery if eligible, recuperation, then chemo and radiation.

FDA 98

FDA Insurance Chemotherapy Documentation 98

PQA

NOVEMBER 1, 2024

Monitoring Oral Chemotherapy Outcomes A new study by specialty pharmacists from Vanderbilt Specialty Pharmacy detailed that a tailored clinical monitoring schedule focused on oral oncolytics with high rates of adverse events (AEs) slashed treatment interruptions by more than 50% and significantly reduced medication-related hospitalizations.

Specialty Pharmacies 52

Specialty Pharmacies Vaccines Chemotherapy Immunization 52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

In this exclusive webinar, Dr. Ben Locwin will discuss the potential effects of this draft, along with the pharmacological and toxicological considerations for optimizing doses of prescription drugs. This new guidance will clearly impact the clinical research field, but how?

FDA

pharmaphorum

JANUARY 27, 2021

pharmaphorum’s Unlocking Health Data to Improve Oncology Outcomes webinar sought to answer these questions by analysing how existing NHS data can be used in innovative ways to make informed decisions about drug research, discovery and value. Improving treatment pathways and outcomes.

Patient Care 143

Patient Care Hospitals Chemotherapy Vaccines 143